PERIPHERAL NEUROPATHY IN THE MPACT STUDY

  • 54% of patients experienced peripheral neuropathy of any grade (227/421)
  • In the 17% of patients who experienced Grade 3 peripheral neuropathy (70/421), it improved to ≤ Grade 1 in less than 1 month (median of 29 days)
  • 8% of patients who received ABRAXANE + gemcitabine permanently discontinued ABRAXANE due to peripheral neuropathy

APPROPRIATE DOSE MODIFICATIONS FOR PERIPHERAL NEUROPATHY

Assessing the severity of peripheral neuropathy is key to determining dose modifications
No recommended for Dose modification of ABRAXANE for peripheral neuropathy: Grade 1 or 2 No recommended for Dose modification of ABRAXANE for peripheral neuropathy: Grade 1 or 2
ABRAXANE Dose modification for peripheral neuropathy: Grade ≥3 ABRAXANE Dose modification for peripheral neuropathy: Grade ≥3
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRAXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL